Welcome to Raystarbio!Focus On Forefront Bioactive Compounds.
Find Your Distributors

Select Your Country or Region

$ USD

You are here:Home-Inhibitors & Agonists-Immunology/Inflammation-NOD-like Receptor (NLR)

Request The Product List ofNOD-like Receptor (NLR) NOD-like Receptor (NLR)

Nucleotide oligomerization domain (NOD)-like receptors (NLRs) are a specialized group of intracellular proteins that play a critical role in the regulation of the host innate immune response. NLRs act as scaffolding proteins that assemble signaling platforms that trigger nuclear factor-κB and mitogen-activated protein kinase signaling pathways and control the activation of inflammatory caspases. Importantly, mutations in several members of the NLR family have been linked to a variety of inflammatory diseases consistent with these molecules playing an important role in host-pathogen interactions and the inflammatory response. NLRs including Nod1 and Nod2 are thought to be kept in an inactive state by intra-molecular interactions.

The central role of the Nod-like receptor (NLR) protein family became increasingly appreciated in innate immune responses. NLRs are classified as part of the signal transduction ATPases with numerous domains (STAND) clade within the AAA+ ATPase family.

Cat. No. Product Name CAS No. Information
GY03987

MCC950 sodium

256373-96-3

MCC950 (CP-456773) is a potent, selective, small-molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 and 8.1 nM in BMDM and HMDM, respectively, specifically inhibits activation of NLRP3, does not inhibit NLRC4, AIM2, TLR signalling or priming of NLRP3; blocks NLRP3 induced ASC oligomerization, does not block K+ efflux, Ca2+ flux or NLRP3-ASC interactions; reduces interleukin-1β (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), rescues neonatal lethality in mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome

GY03910

ML130

799264-47-4

A potent and selective NOD1 inhibitor with IC50 of 0.56 uM; no inhibition on NOD1, TNFα (IC50> 20 uM) and dIKKγ/NEMO, MYD88, FLIP, CARD6, APAF1 or NLRC4; inhibits IL-8 production induced by NOD1 ligand and γ-tri-DAP-induced expression of the prototypical NF-κB target gene IκBα at the mRNA level.

GY03897

INF39

866028-26-4

INF39 (NLRP3 inhibitor INF39) is a nontoxic, irreversible, orally available NLRP3 inhibitor that inhibits NLRP3 ATPase and decreases interleukin-1β release from macrophages; significantly inhibit ATP- and nigericin-induced IL-1β release in mouse bone marrow derived macrophages (BMDM) at 10 uM, reduces colonic myeloperoxidase, IL-1β, and TNF Levels in DNBS-treated rats.

GY05206

NBC19

2068818-75-5

NBC19 is a potent inhibitor of NLRP3 inflammasome, inhibits nigericin-induced ASC speck formation in post-differentiated THP1 cells with IC50 of 60 nM.

GY05315

NOD-IN-1

132819-92-2

A potent, dual inhibitor of NOD1 and NOD2 with IC50 of 5.74 uM and 6.45 uM, respectively; is 7-fold less potent than Noditinib-1 in terms of NOD1 inhibition and completely devoid of selective activity for NOD1 or NOD2 as opposed to Noditinib-1.

GY05193

MCC950

210826-40-7

MCC950 (CP-456773) is a potent, selective, small-molecule inhibitor of NLRP3 inflammasome with IC50 of 7.5 and 8.1 nM in BMDM and HMDM, respectively, specifically inhibits activation of NLRP3, does not inhibit NLRC4, AIM2, TLR signalling or priming of NLRP3; blocks NLRP3 induced ASC oligomerization, does not block K+ efflux, Ca2+ flux or NLRP3-ASC interactions; reduces interleukin-1β (IL-1β) production in vivo and attenuates the severity of experimental autoimmune encephalomyelitis (EAE), rescues neonatal lethality in mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome

GY05192

JC-171

2112809-98-8

JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM; interferes with NLRP3/ASC interaction induced by LPS/ATP stimulation both in vtiro and in vivo; delays the progression and reduces the severity of experimental autoimmune encephalomyelitis (EAE).

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 RayStarBio. All Rights Reserved. Products are only for research use